Specialty Pharmacy ContinuumASHP Calls on HHS to Halt Lilly’s 340B Data Cutoff

⚖️ Legal / Ethical Complexity

Eli Lilly expanded its 340B claims-data requirement in February 2026 to cover in-house hospital pharmacy dispensing and medically administered drugs, demanding submission of approximately 18 pharmacy and 14 medical claims data fields to the 340B ESP platform within 45 to 60 days of dispensing or loss of ceiling-price access. ASHP and covered entity legal counsel are contesting the demands as extra-statutory, while HRSA has not publicly responded and other manufacturers are pursuing similar policies.

What’s at Stake

• 340B ceiling-price access for safety-net hospitals, FQHCs, and rural referral centers depends on program savings that Lilly’s data demands effectively condition, raising the operational cost of compliance above what the statute contemplates, according to ASHP
• Smaller and rural covered entities face disproportionate pressure: limited legal resources and acute financial dependence on 340B discounts leave them with little leverage to contest demands, and several have already submitted data under duress
• The contract pharmacy precedent is now being extended to in-house dispensing, a structural expansion that 340B legal counsel compares to iterative boundary-testing; multiple other manufacturers have begun issuing similar demands in recent weeks
• 11 states have enacted laws explicitly prohibiting manufacturers from conditioning 340B drug distribution on claims data submission, but enforcement is uneven and manufacturers are actively challenging those statutes in court

What to Watch

• Track HRSA enforcement response to ASHP’s June 2 letter and any HHS or state attorney general intervention before threatened cutoffs take broader effect
• Follow alternative dispute resolution and HRSA complaint filings by covered entities that have lost access, which establish the formal record for regulatory or judicial challenge
• Anticipate additional manufacturer data demands across portfolios beyond Lilly, as legal counsel reports several manufacturers moved in the same direction in June
• Monitor the 340B rebate pilot revival by HRSA, which covered entity advocates characterize as a parallel restriction that compounds the data-demand threat
• Engage with ASHP and state pharmacy association advocacy channels during any open comment or legislative windows on 340B program reform